3 US Pharma Mid-Cap Execs to Know
The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their…
Tagged with Eisai
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Japanese Pharma’s Skyrocketing US Footprint
Following PharmaBoardroom’s recent interview with Ivan Cheung, chairman of Eisai’s US affiliate and president of Eisai’s global neurology…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
China’s 3rd Drug Procurement Round: A Bloodbath for…
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in…
Sweden’s BioArctic: A Potential Paradigm Shift in Alzheimer’s…
Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the…
Fendy Yanhui Feng – President, Eisai China
Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant…
Biogen: The Only Hope for Alzheimer’s?
After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field…
Brexit: A Serious Threat to Patients
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit…
Interview: Gary Hendler – Chairman & CEO, Eisai EMEA
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of…
Interview with Philip E. Tan President Director of Eisai…
Eisai has a history of more than 40 years in Indonesia. In fact, the country was one of the first places for the Group to expand into outside of…
Interview with Gary Hendler, President & Chief Executive…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared…
